Dubuque Bank & Trust’s CRISPR Therapeutics CRSP Stock Holding History

Dubuque Bank & Trust’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,870	Closed	-$217K	–	252
2021 Q4	$217K	Sell	2,870 -3	-0.1%	-$262	0.02%	232
2021 Q3	$322K	Hold	2,873	–	–	0.04%	188
2021 Q2	$465K	Hold	2,873	–	–	0.05%	165
2021 Q1	$350K	Hold	2,873	–	–	0.04%	190
2020 Q4	$440K	Hold	2,873	–	–	0.05%	161
2020 Q3	$240K	Buy	+2,873	New	+$255K	0.04%	183
2019 Q2	–	Sell	-2,873	Closed	-$103K	–	252
2019 Q1	$103K	Buy	2,873 +1,448	+102%	+$50.1K	0.02%	209
2018 Q4	$41K	Hold	1,425	–	–	0.01%	289
2018 Q3	$63K	Hold	1,425	–	–	0.01%	246
2018 Q2	$84K	Hold	1,425	–	–	0.01%	278
2018 Q1	$65K	Hold	1,425	–	–	0.01%	312
2017 Q4	$33K	Hold	1,425	–	–	0.01%	380
2017 Q3	$25K	Hold	1,425	–	–	﹤0.01%	391
2017 Q2	$23K	Hold	1,425	–	–	0.01%	386
2017 Q1	$31K	Buy	+1,425	New	+$28K	0.01%	372

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dubuque Bank & Trust's CRSP Position: Q1 2022 in Review

Dubuque Bank & Trust sold out of CRISPR Therapeutics (CRSP) in Q1 2022, closing a stake of 2,870 shares — an estimated $217K sold.

Dubuque Bank & Trust first reported a position in CRSP in Q1 2017 and held it in 15 quarters. The position peaked at $465K in Q2 2021. 447 funds tracked by Wall St. Rank hold CRSP as of Q1 2022.

Dubuque Bank & Trust reported no remaining CRISPR Therapeutics position as of Q1 2022 after selling out during the quarter.
Dubuque Bank & Trust sold 2,870 CRISPR Therapeutics shares in Q1 2022, an estimated $217K.
Dubuque Bank & Trust first reported a position in CRISPR Therapeutics in Q1 2017 and held it in 15 quarters.
Dubuque Bank & Trust's CRISPR Therapeutics position peaked at $465K in Q2 2021.
447 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2022.

Based on Dubuque Bank & Trust's 13F filing for Q1 2022, filed 3 May 2022.